Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 5, 2014, Pages 567-575

  Diamond, Joshua M ^a   Akimova, Tatiana ^b   Kazi, Altaf ^a   Shah, Rupal J ^a   Cantu, Edward ^a   Feng, Rui ^a   Levine, Matthew H ^c   Kawut, Steven M ^a   Meyer, Nuala J ^a   Lee, James C ^a   Hancock, Wayne W ^b   Aplenc, Richard ^b,d   Ware, Lorraine B ^e,f   Palmer, Scott M ^g   Bhorade, Sangeeta ^h   Lama, Vibha N ⁱ   Weinacker, Ann ^j   Orens, Jonathan ^k   Wille, Keith ^l   Crespo, Maria ^m   Lederer, David J ⁿ   Arcasoy, Selim ⁿ   Demissie, Ejigayehu ^a   Christie, Jason D ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Pathology and Laboratory Medicine ^*  (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^j STANFORD UNIVERSITY   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l University of Alabama at Birmingham   (United States)

^m UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁿ Division of Pulmonary Allergy and Critical Care Medicine Department of Medicine Johns Hopkins University Hospital ^*  (United States)

more..

Author keywords

Lung tra

Indexed keywords

ARGININE; HISTIDINE; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; RECEPTOR SUBTYPE;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIMARY GRAFT DYSFUNCTION; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; DINOPROSTONE; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMARY GRAFT DYSFUNCTION; PROSPECTIVE STUDIES; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; T-LYMPHOCYTES, REGULATORY;

EID: 84895550130     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201307-1283OC     Document Type: Article

References (81)

1. Arcasoy SM, Fisher A, Hachem RR, Scavuzzo M, Ware LB; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT working group on primary lung graft dysfunction. Part V: Predictors and outcomes. J Heart Lung Transplant 2005;24: 1483-1488.
2. Bharat A, Kuo E, Steward N, Aloush A, Hachem R, Trulock EP, Patterson GA, Meyers BF, Mohanakumar T. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg 2008;86:189-195; discussion 196-187.
3. Christie JD, Bellamy S, Ware LB, Lederer D, Hadjiliadis D, Lee J, Robinson N, Localio AR, Wille K, Lama V, et al. Construct validity of the definition of primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2010;29:1231-1239.
4. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT working group on primary lung graft dysfunction. Part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005;24:1454-1459.
5. Christie JD, Kotloff RM, Ahya VN, Tino G, Pochettino A, Gaughan C, DeMissie E, Kimmel SE. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005; 171:1312-1316.
6. Christie JD, Van Raemdonck D, de Perrot M, Barr M, Keshavjee S, Arcasoy S, Orens J; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT working group on primary lung graft dysfunction. Part I: Introduction and methods. J Heart Lung Transplant 2005;24:1451-1453.
7. Daud SA, Yusen RD, Meyers BF, Chakinala MM, Walter MJ, Aloush AA, Patterson GA, Trulock EP, Hachem RR. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007;175:507-513.
8. Whitson BA, Prekker ME, Herrington CS, Whelan TP, Radosevich DM, Hertz MI, Dahlberg PS. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 2007;26:1004-1011.
9. Christie JD, Ma SF, Aplenc R, Li M, Lanken PN, Shah CV, Fuchs B, Albelda SM, Flores C, Garcia JG. Variation in the myosin light chain kinase gene is associated with development of acute lung injury after major trauma. Crit Care Med 2008;36:2794-2800.
10. Christie JD, Wurfel MM, Feng R, O'Keefe GE, Bradfield J, Ware LB, Christiani DC, Calfee CS, Cohen MJ, Matthay M, et al.; Trauma ALI SNP Consortium (TASC) investigators. Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma. PLoS ONE 2012;7:e28268.
11. Meyer NJ, Li M, Feng R, Bradfield J, Gallop R, Bellamy S, Fuchs BD, Lanken PN, Albelda SM, Rushefski M, et al. ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. Am J Respir Crit Care Med 2011;183:1344-1353.
12. Diamond JM, Meyer NJ, Feng R, Rushefski M, Lederer DJ, Kawut SM, Lee JC, Cantu E, Shah RJ, Lama VN, et al.; Lung Transplant Outcomes Group. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2012;186:546-552.
13. Bobadilla JL, Love RB, Jankowska-Gan E, Xu Q, Haynes LD, Braun RK, Hayney MS, Munoz del Rio A, Meyer K, Greenspan DS, et al. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 2008;177: 660-668.
14. Christie JD, Robinson N, Ware LB, Plotnick M, De Andrade J, Lama V, Milstone A, Orens J, Weinacker A, Demissie E, et al. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 2007;175:69-74.
15. Covarrubias M, Ware LB, Kawut SM, De Andrade J, Milstone A, Weinacker A, Orens J, Lama V, Wille K, Bellamy S, et al.; Lung Transplant Outcomes Group. Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007;7: 2573-2578.
16. Diamond JM, Kawut SM, Lederer DJ, Ahya VN, Kohl B, Sonett J, Palmer SM, Crespo M, Wille K, Lama VN, et al.; Lung Transplant Outcomes Group. Elevated plasma Clara cell secretory protein concentration is associated with high-grade primary graft dysfunction. Am J Transplant 2011;11:561-567.
17. Diamond JM, Lederer DJ, Kawut SM, Lee J, Ahya VN, Bellamy S, Palmer SM, Lama VN, Bhorade S, Crespo M, et al.; Lung Transplant Outcomes Group. Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis. Am J Transplant 2011;11:2517-2522.
18. Hoffman SA, Wang L, Shah CV, Ahya VN, Pochettino A, Olthoff K, Shaked A, Wille K, Lama VN, Milstone A, et al.; Lung Transplant Outcomes Group. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. Am J Transplant 2009;9:389-396.
19. Iwata T, Philipovskiy A, Fisher AJ, Presson RG Jr, Chiyo M, Lee J, Mickler E, Smith GN, Petrache I, Brand DB, et al. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008;181:5738-5747.
20. Kawut SM, Okun J, Shimbo D, Lederer DJ, De Andrade J, Lama V, Shah A, Milstone A, Ware LB, Weinacker A, et al.; Lung Transplant Outcomes Group. Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation. Chest 2009;136:237-244.
21. Krenn K, Klepetko W, Taghavi S, Lang G, Schneider B, Aharinejad S. Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction. Am J Transplant 2007;7:700-706.
22. Moreno I, Vicente R, Ramos F, Vicente JL, Barberá M. Determination of interleukin-6 in lung transplantation: association with primary graft dysfunction. Transplant Proc 2007;39:2425-2426.
23. Barreiro LB, Ben-Ali M, Quach H, Laval G, Patin E, Pickrell JK, Bouchier C, Tichit M, Neyrolles O, Gicquel B, et al. Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense. PLoS Genet 2009;5:e1000562.
24. Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, Izagirre N, Syafruddin D, Kibiki G, Cristea T, Hijmans A, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA 2007;104:16645-16650.
25. Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, Musser JM. Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS ONE 2007;2:e1318.
26. Plantinga TS, Ioana M, Alonso S, Izagirre N, Hervella M, Joosten LA, van der Meer JW, de la Rú a C, Netea MG. The evolutionary history of TLR4 polymorphisms in Europe. J Innate Immun 2012;4:168-175.
27. Tindall EA, Hayes VM. Comprehensive sequence analysis of the human IL23A gene defines new variation content and high rate of evolutionary conservation. DNA Res 2010;17:117-122.
28. Vasseur E, Patin E, Laval G, Pajon S, Fornarino S, Crouau-Roy B, Quintana-Murci L. The selective footprints of viral pressures at the human RIG-I-like receptor family. Hum Mol Genet 2011;20: 4462-4474.
29. Xu Z, Balsara RD, Gorlatova NV, Lawrence DA, Castellino FJ, Ploplis VA. Conservation of critical functional domains in murine plasminogen activator inhibitor-1. J Biol Chem 2004;279: 17914-17920.
30. Awad M, Pravica V, Perrey C, El Gamel A, Yonan N, Sinnott PJ, Hutchinson IV. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol 1999;60:343-346.
31. El-Gamel A, Awad MR, Hasleton PS, Yonan NA, Hutchinson JA, Campbell CS, Rahman AH, Deiraniya AK, Sinnott PJ, Hutchinson IV. Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant 1999;18:517-523.
32. Kastelijn EA, van Moorsel CH, Rijkers GT, Ruven HJ, Karthaus V, Kwakkel-van Erp JM, van de Graaf EA, Zanen P, van Kessel DA, Grutters JC, et al. Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 2010;29:665-671.
33. Kastelijn EA, van Moorsel CH, Ruven HJ, Karthaus V, Kwakkel-van Erp JM, van de Graaf EA, Zanen P, van Kessel DA, Grutters JC, van den Bosch JM. Genetic polymorphisms in MMP7 and reduced serum levels associate with the development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010; 29:680-686.
34. Kastelijn EA, van Moorsel CH, Ruven HJ, Lammers JW, Grutters JC. Genetic polymorphisms and bronchiolitis obliterans syndrome after lung transplantation: promising results and recommendations for the future. Transplantation 2012;93:127-135.
35. Kwakkel-van Erp JM, van de Graaf EA, Paantjens AW, van Ginkel WG, Schellekens J, van Kessel DA, van den Bosch JM, Otten HG. The killer immunoglobulin-like receptor (KIR) group A haplotype is associated with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2008;27:995-1001.
36. Munster JM, van der Bij W, Breukink MB, van der Steege G, Zuurman MW, Hepkema BG, Verschuuren EA, van Son WJ, Seelen MA. Association between donor MBL promoter haplotype and graft survival and the development of BOS after lung transplantation. Transplantation 2008;86:1857-1863.
37. Palmer SM, Burch LH, Davis RD, Herczyk WF, Howell DN, Reinsmoen NL, Schwartz DA. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168:628-632.
38. Palmer SM, Burch LH, Trindade AJ, Davis RD, Herczyk WF, Reinsmoen NL, Schwartz DA. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 2005;171: 780-785.
39. Palmer SM, Klimecki W, Yu L, Reinsmoen NL, Snyder LD, Ganous TM, Burch L, Schwartz DA. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant 2007;7:693-699.
40. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, Galver L, Barrett JC, Grant SF, Farlow DN, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS ONE 2008;3:e3583.
41. Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, Lederer DJ, Cantu E, Kohl BA, Lama VN, et al.; Lung Transplant Outcomes Group. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013;187: 527-534.
42. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575.
43. Meyer NJ, Feng R, Li M, Zhao Y, Sheu CC, Tejera P, Gallop R, Bellamy S, Rushefski M, Lanken PN, et al. IL1rn coding variant is associated with lower risk of acute respiratory distress syndrome and increased plasma IL1ra. Am J Respir Crit Care Med 2013;187:950-959.
44. Tejera P, Meyer NJ, Chen F, Feng R, Zhao Y, O'Mahony DS, Li L, Sheu CC, Zhai R, Wang Z, et al. Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin. J Med Genet 2012;49:671-680.
45. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, Attar-Cohen H, Ingle C, Beazley C, Gutierrez Arcelus M, Sekowska M, et al. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 2009;325:1246-1250.
46. Yang TP, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, Stranger BE, Deloukas P, Dermitzakis ET. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 2010;26:2474-2476.
47. Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, Wang HH, Yao A, Chen YT, Hsu CN. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 2006;34:W635-W641.
48. Akimova T, Kamath BM, Goebel JW, Meyers KEC, Rand EB, Hawkins A, Levine MH, Bucuvalas JC, Hancock WW. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. Am J Transplant 2012;12: 3449-3461.
49. Meyre D, Farge M, Lecoeur C, Proenca C, Durand E, Allegaert F, Tichet J, Marre M, Balkau B, Weill J, et al. R125W coding variant in TBC1D1 confers risk for familial obesity and contributes to linkage on chromosome 4p14 in the French population. Hum Mol Genet 2008; 17:1798-1802.
50. Stone S, Abkevich V, Russell DL, Riley R, Timms K, Tran T, Trem D, Frank D, Jammulapati S, Neff CD, et al. TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition. Hum Mol Genet 2006;15:2709-2720.
51. Lederer DJ, Kawut SM, Wickersham N, Winterbottom C, Bhorade S, Palmer SM, Lee J, Diamond JM, Wille KM, Weinacker A, et al.; Lung Transplant Outcomes Group. Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med 2011;184:1055-1061.
52. Konya V, Ullen A, Kampitsch N, Theiler A, Philipose S, Parzmair GP, Marsche G, Peskar BA, Schuligoi R, Sattler W, et al. Endothelial etype prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking. J Allerg Clin Immunol 2013;131:532-540 e532.
53. Soontrapa K, Honda T, Sakata D, Yao C, Hirata T, Hori S, Matsuoka T, Kita Y, Shimizu T, Kabashima K, et al. Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc Natl Acad Sci USA 2011;108:6668-6673.
54. Tang EH, Libby P, Vanhoutte PM, Xu A. Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. J Cardiovasc Pharmacol 2012;59:116-123.
55. Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, Ferraro F, et al. Differential stemand progenitor-cell trafficking by prostaglandin E2. Nature 2013;495: 365-369.
56. Baratelli F, Lin Y, Zhu L, Yang SC, Heuzé-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD41 T cells. J Immunol 2005;175:1483-1490.
57. Lee BP, Juvet SC, Zhang L. Prostaglandin E2 signaling through E prostanoid receptor 2 impairs proliferative response of double negative regulatory T cells. Int Immunopharmacol 2009;9:534-539.
58. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-3814.
59. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-249.
60. Yue P, Melamud E, Moult J. SNPs3D: candidate gene and SNP selection for association studies. BMC Bioinformatics 2006;7:166.
61. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M; ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57-74.
62. D'Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF, Pipeling MR, Brower RG, Tuder RM, McDyer JF, et al. CD41CD251Foxp31 Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest 2009; 119:2898-2913.
63. Pietropaoli A, Georas SN. Resolving lung injury: a new role for Tregs in controlling the innate immune response. J Clin Invest 2009;119: 2891-2894.
64. Garibaldi BT, D'Alessio FR, Mock JR, Files DC, Chau E, Eto Y, Drummond MB, Aggarwal NR, Sidhaye V, King LS. Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment. Am J Respir Cell Mol Biol 2013;48:35-43.
65. Sun J, Han ZB, Liao W, Yang SG, Yang Z, Yu J, Meng L, Wu R, Han ZC. Intrapulmonary delivery of human umbilical cord mesenchymal stem cells attenuates acute lung injury by expanding CD41CD251 forkhead boxp3 (Foxp3)1 regulatory T cells and balancing antiand pro-inflammatory factors. Cell Physiol Biochem 2011;27: 587-596.
66. Kuzumoto Y, Sho M, Ikeda N, Hamada K, Mizuno T, Akashi S, Tsurui Y, Kashizuka H, Nomi T, Kubo A, et al. Significance and therapeutic potential of prostaglandin E2 receptor in hepatic ischemia/ reperfusion injury in mice. Hepatology 2005;42:608-617.
67. Hishikari K, Suzuki J, Ogawa M, Isobe K, Takahashi T, Onishi M, Takayama K, Isobe M. Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. Cardiovasc Res 2009;81: 123-132.
68. Nomi T, Sho M, Akahori T, Kanehiro H, Nakajima Y. Protective effect of prostaglandin E2 receptors EP2 and EP4 in alloimmune response in vivo. Transplant Proc 2006;38:3209-3210.
69. Hristovska AM, Rasmussen LE, Hansen PB, Nielsen SS, Nü sing RM, Narumiya S, Vanhoutte P, Skøtt O, Jensen BL. Prostaglandin E2 induces vascular relaxation by E-prostanoid 4 receptor-mediated activation of endothelial nitric oxide synthase. Hypertension 2007;50: 525-530.
70. Wang Y, Geer LY, Chappey C, Kans JA, Bryant SH. Cn3D: sequence and structure views for Entrez. Trends Biochem Sci 2000;25: 300-302.
71. Nitz I, Fisher E, Grallert H, Li Y, Gieger C, Rubin D, Boeing H, Spranger J, Lindner I, Schreiber S, et al. Association of prostaglandin E synthase 2 (PTGES2) Arg298His polymorphism with type 2 diabetes in two German study populations. J Clin Endocrinol Metab 2007;92: 3183-3188.
72. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD41 CD251 T regulatory cell activities in lung cancer. Cancer Res 2005;65: 5211-5220.
73. Hamberg M, Samuelsson B. On the metabolism of prostaglandins E1 and E2 in man. J Biol Chem 1971;246:6713-6721.
74. Samuelsson B, Granström E, Green K, Hamberg M, Hammarström S. Prostaglandins. Annu Rev Biochem 1975;44:669-695.
75. Chadt A, Leicht K, Deshmukh A, Jiang LQ, Scherneck S, Bernhardt U, Dreja T, Vogel H, Schmolz K, Kluge R, et al. Tbc1d1 mutation in lean mouse strain confers leanness and protects from diet-induced obesity. Nat Genet 2008;40:1354-1359.
76. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ, Mathes WF, Przypek R, Kanarek R, Maratos-Flier E. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996;380:243-247.
77. Shafey M, Anderson JL, Scarvelis D, Doucette SP, Gagnon F, Wells PS. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 2007;97:635-641.
78. Lau CL, Zhao Y, Kim J, Kron IL, Sharma A, Yang Z, Laubach VE, Linden J, Ailawadi G, Pinsky DJ. Enhanced fibrinolysis protects against lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2009;137: 1241-1248.
79. Shah RJ, Bellamy SL, Localio AR, Wickersham N, Diamond JM, Weinacker A, Lama VN, Bhorade S, Belperio JA, Crespo M, et al. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. J Heart Lung Transplant 2012;31:942-949.
80. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, et al. Strengthening the reporting of genetic association studies (STREGA): An extension of the strobe statement. Ann Intern Med 2009;150:206-215.
81. Cantu E, Lederer DJ, Meyer K, Milewski K, Suzuki Y, Shah RJ, Diamond JM, Meyer NJ, Tobias JW, Baldwin DA, et al.; CTOT Investigators. Gene set enrichment analysis identifies key innate immune pathways in primary graft dysfunction after lung transplantation. Am J Transplant 2013;13:1898-1904.